Anthony L Williams
CIK 1635534 · View on SEC EDGAR ↗
First SEC filing: March 5, 2015 · Latest: March 5, 2015
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| March 7, 2019 | GMED | S | 37,826 | $46.01 | $1,740,374 | 0 Direct | -100.00% | Disposed | 91.8% (price as of 2026-08-19) |
| March 6, 2019 | GMED | S | 8,386 | $46.14 | $386,930 | 0 Direct | -100.00% | Disposed | 91.2% (price as of 2026-08-19) |
| March 5, 2019 | GMED | S | 165,870 | $47.05 | $7,804,184 | 0 Direct | -100.00% | Disposed | 87.5% (price as of 2026-08-19) |
| June 11, 2018 | GMED | S 10b5-1 | 1,400 | $56.87 | $79,618 | 0 Direct | -100.00% | Disposed | 55.2% (price as of 2026-08-19) |
| June 11, 2018 | GMED | S 10b5-1 | 120,267 | $56.14 | $6,751,789 | 1,400 Direct | -98.85% | Disposed | 57.2% (price as of 2026-08-19) |
| Dec. 13, 2017 | GMED | S 10b5-1 | 15,000 | $38.30 | $574,500 | 0 Direct | -100.00% | Disposed | 130.4% (price as of 2026-08-19) |
| June 5, 2017 | GMED | S 10b5-1 | 16,153 | $31.94 | $515,927 | 0 Direct | -100.00% | Disposed | 176.3% (price as of 2026-08-19) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| March 7, 2019 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (37,826) | $26.27 | Jan. 30, 2027 | 37,826 | Disposed |
| March 6, 2019 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (5,507) | $26.27 | Jan. 30, 2027 | 5,507 | Disposed |
| March 6, 2019 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (2,879) | $43.77 | Jan. 22, 2028 | 2,879 | Disposed |
| March 5, 2019 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (89,583) | $25.65 | July 7, 2025 | 89,583 | Disposed |
| March 5, 2019 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (8,333) | $24.10 | Jan. 20, 2025 | 8,333 | Disposed |
| March 5, 2019 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (20,454) | $43.77 | Jan. 22, 2028 | 20,454 | Disposed |
| March 5, 2019 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (47,500) | $25.52 | Jan. 25, 2026 | 47,500 | Disposed |
| Jan. 22, 2019 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (80,000) | $43.58 | Jan. 22, 2029 | 80,000 | Acquired |
| June 11, 2018 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (41,667) | $24.10 | Jan. 20, 2025 | 41,667 | Disposed |
| June 11, 2018 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (40,000) | $24.42 | June 23, 2024 | 40,000 | Disposed |
| June 11, 2018 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (30,000) | $23.95 | Jan. 23, 2024 | 30,000 | Disposed |
| June 11, 2018 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (10,000) | $13.04 | Jan. 24, 2023 | 10,000 | Disposed |
| Jan. 22, 2018 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (80,000) | $43.77 | Jan. 22, 2028 | 80,000 | Acquired |
| Dec. 13, 2017 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (15,000) | $13.04 | Jan. 24, 2023 | 15,000 | Disposed |
| June 5, 2017 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (16,153) | $11.28 | April 20, 2021 | 16,153 | Disposed |
| Jan. 30, 2017 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (80,000) | $26.27 | Jan. 30, 2027 | 80,000 | Acquired |
| Jan. 25, 2016 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (60,000) | $25.52 | Jan. 25, 2026 | 60,000 | Acquired |
| July 7, 2015 | GMED | Stock Option (Right to Buy Class A Common Stock) | Class A Common Stock (100,000) | $25.65 | July 7, 2025 | 100,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 5 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| March 5, 2015 | GMED | Stock Option (Right to Buy Class A Common Stock)→ Class A Common Stock (16,153) | 16,153 | Direct |
| March 5, 2015 | GMED | Stock Option (Right to Buy Class A Common Stock)→ Class A Common Stock (25,000) | 25,000 | Direct |
| March 5, 2015 | GMED | Stock Option (Right to Buy Class A Common Stock)→ Class A Common Stock (30,000) | 30,000 | Direct |
| March 5, 2015 | GMED | Stock Option (Right to Buy Class A Common Stock)→ Class A Common Stock (40,000) | 40,000 | Direct |
| March 5, 2015 | GMED | Stock Option (Right to Buy Class A Common Stock)→ Class A Common Stock (50,000) | 50,000 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
GMED
President (until March 2019)| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2019 | $393,382 | — | — | $1,054,268 | — | — | $12,592 | $1,460,242 |
| 2018 | $381,924 | — | — | $1,087,147 | $369,250 | — | $32,152 | $1,870,473 |
| 2017 | $370,800 | — | — | $666,149 | $369,250 | — | $32,064 | $1,438,263 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.